In Vitro Hemocompatibility of the BiVACOR Total Artificial Heart in Continuous and Pulsatile Flow
Artificial Organs · 2026-01 · 50 (1) · 84-93
DOI: 10.1111/aor.70009 ↗Kurz gefasst
Fachartikel in der Zeitschrift Artificial Organs, online erschienen am 17.09.2025. Verfasst von Antony P McNamee und 6 weiteren Autor:innen. Beteiligte Einrichtung: Biorheology Research Laboratory, Griffith University, Gold Coast, Australia. Hauptthemen laut MEDLINE: Heart, Artificial, Heart-Assist Devices. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Medical Research Future Fund, Australian Research Council.
Abstract (Originalsprache)
Background
Heart transplantation is curative for advanced heart failure; however, the limited availability of suitable donor organs makes mechanical circulatory support devices a crucial alternative. BiVACOR's total artificial heart (TAH) is a new device that provides full replacement of the organic failing heart to support systemic and pulmonary circulation using a single, magnetically levitated centrifugal rotor. The aim of this study was to assess the in vitro hemocompatibility of the TAH operating in either continuous flow (CF) or pulsatile flow (PF) mode.
Methods
Cattle blood was circulated in an in vitro blood loop at 5 L/min against 100 mmHg for 6 h using the TAH in CF ( n = 6) or PF ( n = 6), which were compared with a reference pump (CentriMag; n = 6). Blood analysis included hematology, plasma free‐hemoglobin, and von Willebrand factor (vWF) multimers.
Results
The normalized indexes of hemolysis were 0.004 ± 0.003 g/100 L for CF, 0.004 ± 0.003 g/100 L for PF, and 0.003 ± 0.002 g/100 L for reference. Basic hematology and vWF multimers were affected in a linear manner, but did not vary between flow regimes or devices.
Conclusions
BiVACOR's TAH operated in a manner requisite of complete heart support, generated comparable in vitro blood compatibility to the clinically approved reference pump, as evidenced by hematological parameters and vWF analyses. The presence of a large pulse pressure did not impact hemocompatibility, which is a positive sign for future applications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Biorheology Research Laboratory, Griffith University, Gold Coast, Australia.
- BiVACOR Inc., Huntington Beach, California, USA.
- BiVACOR Australia, Gold Coast, Australia.
- School of Engineering and Built Environment, Griffith University, Gold Coast, Australia.
ORCID-Profile: Antony P McNamee
Förderung
- Medical Research Future Fund
- Australian Research Council
Zitieren
APA
McNamee, A. P., Timms, D., Nestler, F., Bartnikowski, N., Smith, A., Tansley, G. D., & Simmonds, M. J. (2026). In Vitro Hemocompatibility of the BiVACOR Total Artificial Heart in Continuous and Pulsatile Flow. Artificial Organs, 50(1), 84-93. https://doi.org/10.1111/aor.70009
Vancouver
McNamee AP, Timms D, Nestler F, Bartnikowski N, Smith A, Tansley GD, et al. In Vitro Hemocompatibility of the BiVACOR Total Artificial Heart in Continuous and Pulsatile Flow. Artificial Organs. 2026;50(1):84-93. doi:10.1111/aor.70009
BibTeX
@article{McNamee2026,
author = {McNamee, Antony P and Timms, Daniel and Nestler, Frank and Bartnikowski, Nicole and Smith, Amanda and Tansley, Geoff D and Simmonds, Michael J},
title = {In Vitro Hemocompatibility of the BiVACOR Total Artificial Heart in Continuous and Pulsatile Flow},
journal = {Artificial Organs},
year = {2026},
volume = {50},
number = {1},
pages = {84--93},
doi = {10.1111/aor.70009}
}
EUVIMED